1 min read

ID: 3865

Discovery Date: 19 August 2021, 07:16:22 UTC

Published Date: 2021-08-31 23:00:00

Source: The Lancet

Link: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00250-7/fulltext

Manual Selection: true

Machine Learning Gaussian Naive Bayes Model: true


Over the past 30 years increasing numbers of molecules have been developed for treatment of multiple sclerosis. However, given the heterogeneity of the disease and the fact that many patients have refractory or progressive multiple sclerosis, new therapeutic alternatives are still needed. Tyrosine kinases are enzymes that mediate phosphorylation of tyrosine residues on downstream molecules that participate in signalling pathways. These kinases have crucial roles in cellular proliferation and differentiation, cell growth and metabolism, and survival and apoptosis, making them potential therapeutic targets in various autoimmune and lymphoproliferative diseases. 1 , 2 Bruton’s tyrosine kinase is a cytoplasmic tyrosine kinase expressed by B cells and myeloid cells. 3 Both B cells and myeloid cells (particularly microglia) are important drivers of multiple sclerosis, 4 suggesting that inhibitors of Bruton’s tyrosine kinase, such as the irreversible inhibitors evobrutinib, tolebrutininb, and orelabrutinib, and the reversible inhibitors fenebrutinib and BIIB091, might provide therapeutic benefits for patients.

Noun Phrases in Title

  • BTK inhibitors
  • potential therapies
  • multiple sclerosis
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.